Pre-market hot trades in US stocks: Atlantic up 17.26% in pre-market; Planet Green up 15.91% in pre-market

Pre-market Hot Trades in US Stocks Atlantic, up 17.26% in pre-market, has no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Planet Green is up 15.91% in pre-market. Based on recent news, On February 22, Planet Green reported unusual trading activity of its common stock on the NYSE American. The company stated that it has conducted an investigation but cannot currently determine whether corrective measures are needed, adding that there are no undisclosed significant developments in its business that could explain the market activity. On February 22, Planet Green received a notice from NYSE American stating that it failed to comply with the continued listing standards. The company reported a shareholder deficit of $573,528 as of September 30, 2025, and has incurred losses in the last five fiscal years. The company must submit a plan by January 7, 2026, to regain compliance by June 8, 2027; if it meets other listing rules, its stock will continue to trade during the remediation period. Given recent market volatility, investors should remain cautious. Top Gainers in Pre-market US Stocks Vir Biotechnology is up 46.97% in pre-market. Based on recent key news: On February 24, Vir Biotechnology entered into a collaboration agreement with Astellas Pharma to advance the development and commercialization of its prostate cancer experimental drug VIR-5500. The agreement includes a $335 million upfront payment and recent milestone payments, which are expected to have a significant impact on the company's future growth. Source: Reuters On February 24, Vir Biotechnology reported fourth-quarter revenue of $64 million, far exceeding analysts' expectations of $23.1 million, demonstrating strong financial performance. Source: LSEG On February 24, Vir Biotechnology's Phase I clinical trial results for VIR-5500 were positive, showing good safety and anti-tumor activity, further boosting market confidence. Source: Business Wire The biotechnology industry faces regulatory risks, and market volatility is high. Larimar Therapeutics is up 41.64% in pre-market. Based on recent news, On February 24, Larimar Therapeutics announced that its drug Nomlabofusp received FDA breakthrough therapy designation and reiterated plans to submit a biologics license application by June 2026. This news greatly boosted market confidence, driving the stock price significantly higher. The biopharmaceutical industry has performed strongly recently, and investor sentiment is high Silo Pharma pre-market rose 31.58%. Based on recent key news: On February 23, Silo Pharma announced a $1 million stock repurchase plan. This move is seen as the company's management believing that current market conditions undervalue its stock and aims to enhance shareholder value. Following this announcement, the stock price significantly increased. Source: Reuters On February 23, Silo Pharma released relevant information through the EDGAR system, further confirming the details of the repurchase plan. This move strengthened market confidence in the company's future development. Source: EDGAR On February 23, Silo Pharma's technical sentiment signal indicated a strong sell, but the announcement of the repurchase plan changed market sentiment, driving the stock price up. Source: Public Technologies The biopharmaceutical industry has been volatile recently and requires attention